ICMR and Zydus Lifesciences initiate second phase proof-of-concept trial for Desidustat in patients with sickle cell disease
ICMR partners with Zydus Lifesciences for Desidustat phase-2 trials in sickle cell disease patients, aiming for innovative treatment.
14 Oct 13:39 · The Hindu